Service
Our Services
Novel transdermal formulations
MedRx is well-experienced in developing novel transdermal therapies by capitalizing our proprietary ionic liquid technology, in order to overcome hurdles for conventional transdermal technologies (accomplishing increased solubility and absorbability of APIs / delivery of new therapeutic modalities, etc.). In other word, MedRx is skilled in developing novel treatments by using APIs which are:
- Matching the benefits of transdermal administration route, but rarely passing through the skin under conventional technologies, and / or
- Highly-potential, but failing to fully deliver its intrinsic potentials under oral / other administration routes due to its oral low BA, short durations, and so on.
In this spirit, MedRx is seeking partnering opportunities in order to develop novel therapies in collaboration with partners and partners’ proprietary APIs.
Novel oral formulations
MedRx has found that our Ionic Liquid system may improve / enhance, not limited to the transdermal / topical absorbability, but also the oral absorbability of some APIs. In other word, MedRx's Ionic Liquid system may
Allow APIs with weak absorbability to be available as oral formulations by means of increasing their absorbability.
MedRx is unremittingly working on developing / expanding our Ionic Liquid system and seeking partnering opportunities in order to develop novel therapies in collaboration with partners and partners’ proprietary APIs.
